Tech billionaires are increasingly investing in biotechnology startups focused on anti-aging solutions, with one notable company recently raising $17 million to develop treatments aimed at extending human lifespan. The conversation around anti-aging has intensified, particularly regarding the use of rapamycin, a drug that some believe may slow the aging process. Experts suggest that advancements in biotechnology could lead to significant breakthroughs in longevity, with predictions of achieving Longevity Escape Velocity within the next decade, a point at which life expectancy may increase faster than aging. These developments reflect a growing trend among entrepreneurs and investors to explore innovative solutions for age-related health challenges.